Although studies have demonstrated the efficacy of the new anti-epileptic on the block, pregabalin [LyricaR], in the treatment of Generalized Anxiety Disorder and Social Anxiety Disorder, there is no study so far of such efficacy for the treatment of depression.
This case study in a patient with chronic major depression demonstrates that Pregabalin could be an effective augmenting agent to other anti-depressants, e.g., SSRI’s and SNRI’s.
This added property of Pregabalin may be related to its probable GABA-ergic mechanism of action that could be soon the emerging treatment pathway for achieving better remission in chronic depression that is yet clinically problematic.[GABA-ergic drugs enhance the activity of gamma-aminobutyric acid (GABA) – a neurotransmitter able to induce relaxation, analgesia, and sleep.]
Source: Journal of Psychopharmacology. Nov 2007; 21(8):883-4. PMID: 17984164, by Showraki M. Community Psychiatrists Association of Toronto, Ontario, Canada. [E-mail: email@example.com ]